Furthermore, we separated BRCA1 and BRCA2 in the subgroup analysis, and found that BRCA2 is likely the most important mutation in prostate cancer, and the impact of BRCA1 needs to be clarified in future studies. This evidence concerns the gene BRCA1 and prostate carcinoma.